Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Commentary on “Attention-deficit hyperactivity disorder medication use is associated with testosterone hypofunction”

International Journal of Impotence Research (2024)Cite this article

Subjects

“Attention-Deficit Hyperactivity Disorder Medication Use is Associated with Testosterone Hypofunction – Results from a National Claims Database Analysis” by Ostdiek-Wille et al. [1], investigates a possible link between chronic Attention-Deficit Hyperactivity Disorder (ADHD) stimulant medication use and the associated risk of developing testosterone hypofunction in adult males. The authors used a large-scale dataset from the TriNetX LLC Research Network (TriNetX LLC, Cambridge MA, USA) that likely included a diverse and comprehensive patient population. The authors also planned to create an additional control group that takes into account the population diagnosed with ADHD alone without stimulant use. This increases the reader’s confidence in attributing the difference found in the results to stimulant medication only and eliminates the possible confounding effect of ADHD disease. An additional strength is the longitudinal design and the five-year follow-up period for assessing the occurrence of testicular hypofunction. Furthermore, the researchers employed propensity score matching to control for potential confounding variables, thereby strengthening the validity of their reports.

Despite the large dataset (17,224 men were analyzed in each group) and the appropriate statistical tests that the authors utilized, the study also has some limitations. By nature, the study has a retrospective design, therefore it is not the ideal way to establish causality in a clinical scenario. Additionally, there’s a lack of information on medication dosage which is an important factor to consider when contemplating dose-response gradient assumptions that would otherwise be sought in an adverse event-drug study. An additional limitation is that the most recent patient data goes back to 2019, which is outdated relative to the very recent publication date of December 2023.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ostdiek-Wille GP, Bavitz KC, Kohn TP, Deibert CM. Attention-deficit hyperactivity disorder medication use is associated with testosterone hypofunction-results from a national claims database analysis. Int J Impot Res. 2023. https://doi.org/10.1038/s41443-023-00805-2

    Article  PubMed  Google Scholar 

  2. Chatterjee-Chakrabarty S, Miller BT, Collins TJ, Nagamani M. Adverse effects of methylphenidate on the reproductive axis of adolescent female rats. Fertil Steril. 2005;84 Suppl 2:1131–8.

    Article  CAS  PubMed  Google Scholar 

  3. Khoubbieh F, Erdogan CS, Onel T, Yildirim E, Sumer E, Yaba A, et al. Effect of methylphenidate on the onset of puberty and reproductive organ development in rats. Physiol Behav. 2023;266:114204.

    Article  CAS  PubMed  Google Scholar 

  4. Wang LJ, Huang YH, Chou WJ, Lee SY, Tsai CS, Lee MJ, et al. Potential disturbance of methylphenidate of gonadal hormones or pubescent development in patients with attention-deficit/hyperactivity disorder: a twelve-month follow-up study. Prog Neuropsychopharmacol Biol Psychiatry. 2021;108:110181.

    Article  CAS  PubMed  Google Scholar 

  5. Ramasamy R, Dadhich P, Dhingra A, Lipshultz L. Case report: testicular failure possibly associated with chronic use of methylphenidate. F1000Res. 2014;3:207.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Minnesota, Minneapolis, MN, USA

    Onuralp Ergun

  2. Department of Urology, Hacettepe University, Ankara, Turkey

    Ahmet Gudeloglu

Authors
  1. Onuralp Ergun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ahmet Gudeloglu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

OE: Writing- original draft. AG: Writing- review & editing.

Corresponding author

Correspondence to Onuralp Ergun.

Ethics declarations

Competing interest

Corresponding author (OE) is an associate-editor at IJIR: Your Sexual Medicine Journal but is not involved with any of this manuscript’s processing and/or reviewing stages.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ergun, O., Gudeloglu, A. Commentary on “Attention-deficit hyperactivity disorder medication use is associated with testosterone hypofunction”. Int J Impot Res (2024). https://doi.org/10.1038/s41443-024-00834-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41443-024-00834-5

Search

Advanced search

Quick links